StockData
Design Therapeutics, Inc. logo

Design Therapeutics, Inc. (DSGN) company profile

DSGNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 7/30
$9.84−0.08 (-0.81%)

Close on Nov 17, 2026Market cap $615.80MP/E –Yield –

About Design Therapeutics

Pharmaceutical Preparations, SIC 2834

Design Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutic candidates called GeneTAC molecules. These chimera molecules are designed to treat monogenic degenerative diseases caused by inherited nucleotide repeat expansion mutations, which lead to either protein deficiencies or toxic gene products. The company's lead investigational programs include DT-216P2 for Friedreich ataxia, DT-168 for Fuchs endothelial corneal dystrophy, DT-818 for myotonic dystrophy type-1, and an early-stage research program targeting Huntington's disease. As a clinical-stage entity, the company primarily serves patient populations with these genetic conditions through clinical development and trials.

The company operates in a single operating segment focused on the development of its therapeutic platform and product pipeline. Its clinical trials and nonclinical studies evaluate candidates across multiple indications, including ongoing clinical development in the United States. Design Therapeutics maintains its principal executive offices and headquarters in Carlsbad, California.

Summary of the business section of Design Therapeutics's latest annual report, written by StockData.

Company profile

Company

Legal name
Design Therapeutics, Inc.
Headquarters
Carlsbad, CA
Address
6005 Hidden Valley Road, Suite 110 92011
Phone
(858) 293-4900
Employees
54, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
Ernst & Young LLP, San Diego, California

Stock & identifiers

Ticker
DSGN
Exchange
Nasdaq
IPO date
Mar 26, 2021
Shares outstanding
63M, Jul 29, 2026
Public float
$114.34M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
SEC CIK
1807120
CUSIP
25056L103
ISIN
US25056L1035
FIGI
BBG00SNC49V8
Share class FIGI
BBG00SNC49W7
EIN
82-3929248

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Pratik ShahPresident, CEO and Chairperson, Director154,923
Julie BurgessChief Accounting Officer–
Chris StorgardChief Medical Officer–
Sean JeffriesChief Operating Officer810,283
Simeon GeorgeDirector6,526,476
John P. SchmidDirector57,639
David ShapiroDirector–
Rodney W. LappeDirector133,024
Heather A. BergerDirector1,300
Justin D. GoverDirector–
Arsani WilliamDirector3,655,000
Deepa PrasadDirector1,837,273

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusOption awardsIncentive payOtherTotalvs. prior year
Pratik Shah, Ph.D.
President, Chief Executive Officer and Chairperson
$395.00K$144.00K$2.75M$237.00K$14.00K$3.54M+349%
Sean Jeffries, Ph.D.
Chief Operating Officer
$484.00K$6.40K$1.19M$193.60K$14.00K$1.89M+44%
Chris M. Storgard, M.D.
Chief Medical Officer
$339.31K$144.73K$1.40M$135.72K$14.00K$2.03M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Mar 26, 2021
Offer price
$20.00
Securities offered
12,000,000
Gross proceeds
$240.00M
Exchange
Nasdaq
First trading day
Mar 26, 2021
First-day close
$41.49+107.5%
Lock-up ends (est.)
Sep 22, 2021

“The initial public offering price is $20.00 per share of our common stock.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we had 54 employees, all of whom were full-time, and 20 of whom have a Ph.D.”

Corporate history

Events identified from SEC filings

See a number that looks wrong?